Raymond James Downgrades Verastem (VSTM) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
JMP Securities Downgrades Verastem (VSTM) to Market Perform
September 29, 2015 8:26 AM EDTJMP Securities downgraded Verastem (NASDAQ: VSTM) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.
Shares of Verastem closed at $1.85 yesterday.
... MoreJefferies Downgrades Verastem (VSTM) to Hold
September 28, 2015 4:43 PM EDTJefferies downgraded Verastem (NASDAQ: VSTM) from Buy to Hold with a price target of $2.00 (from $18.00).
For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.
Shares of Verastem closed at $5.67 yesterday.
... MoreUBS Downgrades Verastem (VSTM) to Neutral
September 28, 2015 1:27 PM EDTUBS downgraded Verastem (NASDAQ: VSTM) from Buy to Neutral with a price target of $2.00.
For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.
Shares of Verastem closed at $5.67 yesterday.
... MoreMizuho Securities Downgrades Verastem (VSTM) to Neutral
September 28, 2015 1:25 PM EDTMizuho Securities downgraded Verastem (NASDAQ: VSTM) from Outperform to Neutral with a price target of $2.00 (from $21.00).
Analyst Eric Criscuolo commented, "We are downgrading VSTM from Buy to Neutral and lowering our PT from $21 to $2 following the failure of the COMMAND trial of... More
Roth Capital Downgrades Verastem (VSTM) to Neutral
September 28, 2015 9:37 AM EDTRoth Capital downgraded Verastem (NASDAQ: VSTM) from Buy to Neutral with a price target of $2.00 (from $23.00).
Analyst Joseph Pantginis commented, "There has been a major disappointment this morning as the pivotal COMMAND study using VS-6063 in mesothelioma was halted for futility following the... More
Verastem (VSTM) Ceases VS-6063 Phase 2 Enrollment in Mesothelioma Following DSMB Recommendation
September 28, 2015 7:01 AM EDTVerastem (NASDAQ: VSTM) announced that the Company has stopped enrollment in the Phase 2 registration-directed, double-blind, placebo-controlled study (COMMAND) of VS-6063 for patients with mesothelioma. The decision to stop enrollment for futility followed a Data Safety Monitoring Board (DSMB) review of a pre-planned interim analysis. The results of the analysis demonstrated that VS-6063 had a generally well... More
